Pfizer’s respiratory syncytial virus (RSV) vaccine has been approved by the European Commission (EC) to protect both infants and older adults against RSV-caused lower respiratory tract disease (LRTD).
The EC’s decision allows Abrysvo to be given as a single dose to adults aged 60 years and older, and those who are 32 to 36 weeks into their pregnancy to protect their babies from birth until they are six months old.
RSV is a common contagious virus characterised by several mild, cold-like symptoms. Although most people recover within a week or two, the virus can cause severe illness in young infants and older adults.
The approval, which follows a recent recommendation from the European Medicines Agency’s human medicines committee, was supported by positive results from the late-stage MATISSE and RENOIR trials.
In MATISSE, the vaccine demonstrated 81.8% efficacy in preventing severe medically attended lower respiratory tract illness in infants in the first 90 days after birth, and 69.4% efficacy within 180 days.
At an interim analysis of the ongoing RENOIR trial, the vaccine was 85.7% effective among older adults with two or more symptoms of RSV, and 66.7% for two or more symptoms.
Annaliesa Anderson, senior vice president and head of vaccine research and development at Pfizer, said the approval marked “significant progress in the scientific community’s efforts to provide meaningful protection against RSV”.
She continued: “The approval of the vaccine for both older adults and infants through maternal immunisation is a triumph for public health and we hope to see a tremendous impact for future seasons.”
by Emily Kimber
Source: pharmatimes.com
After attending the annual Pulmonary Embolism Symposium last week in Austin, Texas, the analysts predicted clinical guidelines could shift toward catheter-based therapy once data from ongoing randomized trials is available.
SAS – the AI and analytics company – has been selected by AstraZeneca to help boost efficiency and drive automation in the delivery of statistical analyses for clinical and post-approval submissions to regulatory authorities.
After the Centers for Medicare & Medicaid Services (CMS) revealed the list of drugs set to face the first round of price negotiations under the Inflation Reduction Act (IRA), the drugmakers responsible for marketing them are confronting a series of deadlines.
